Physiomics Share Discussion Threads

[albert3591] 06/9/2020 19:28

How much tomorrow girls,I say a rise due to rampers followed by a fall.We will see if the suckers are learning.

[hodhasharon] 06/9/2020 19:27

Maybe it’s time to post my evidence.....I’;ll sleep on it.

[albert3591] 06/9/2020 19:25

He would find you are a Dirty Dirty boy,who fantasises a lot.A possible cure to stop following idiot rampers on advfn discussion boards.

[hodhasharon] 06/9/2020 19:19

I wonder what a psychiatrist would make of that post!

[albert3591] 06/9/2020 19:16

It looks like the parasites parade today,they must be worried about the coming week don’t forget to air your tent before you stash away for the winter shoddy.Maybe mummy will let you back into her bed sit if you have a wash and keep your hands to yourself,but I’m afraid stiggy says you are always touching where you shouldn’t.Dirty Dirty boy.

[davevt] 06/9/2020 18:41

No hod, it's a floated company, so has a worth of about 9 million.

That's 256 worth of 35 grands. Do you think they will ever invent 256 cancer drugs?...and then pay 9 million for a company constantly making a loss, and one with expired patents, no i.p, and one that can only dose 1 type of drug.

Also pyc can't be sold, because their data they use in modelling comes from pharmas giving them THEIR data from their own trials for them to work with and build the models from. How do you think they could build models without data in the first place. So if a pharma could buy pyc, it's not like other pharmas in competition with them are going to willingly give a competitor their data 😂 and without that data, the models are useless.

If a pharma was going to buy anyone, it would be the Biotechs that do design and dosing for all drugs...ah, just like the ones that HAVE recently been bought out.

If someone wanted to buy pyc, they would have already, it's been going TWENTY YEARS.

See, a little knowledge of the company, history, and industry goes a long way..

[the stigologist] 06/9/2020 14:48

Snippet from CNBC 2 years back on 'war' between Merck $MRK and Bristol Myers Squibb $BMY Immuno-Oncology drugs Keytruda vs Opdivo

(note they also flash up Roche and Astra Zeneca tickers alongside $BMY and $MRK)

May be of interest to $DDDD #DDDD 4D Pharma ('amplifying Keytruda strategy') and #PYC Physiomics (combination therapies) shareholders

[tonytony4] 06/9/2020 11:14

Hod your right the only posts you will get from our resident derampers are bitterness they either got spiked or sold out to early, Anyway bring on next week let focus on our investment and not pay attention to the Vile derampers/shorters.

[hodhasharon] 06/9/2020 11:10

Dave also makes Some valid arguments. I don’t have a clue what PYC do in all honest, but I know when large players are accumulating, so I’m backing them as always.

The only fundamental I have taken notice of is.....whatever PYC does, a massive pharma wants.

I got rich following the smart money, and I will continue with this strategy until it fails me.

[davevt] 06/9/2020 10:50

Hod, I agree, if you're an idiot and have no idea what pyc does, then you'd think it's 'rich content'.

Here's the facts.

Pyc only do dose estimation for known working cancer drugs, and charge 35k for each one. I mean, seriously, that's all they do, a trivial and minor service that drug companies already DO THEMSELVES. May it be quicker? Sure? More accurate more percent of the times? Maybe? Are they the only company that does it? NOPE. Is it a crucial service? NOPE..

They have been around 20 years and every pharma that exists will already know about them.

The do less turnover than your local pub and have never made a profit, as that isn't their business model.

All of the proper Biotech companies do what little pyc do and a hundred times more, hence why when Stig labels them as 'comparitors' he fails to grasp the fact they are doing hundreds of millions in revenues and have all the pharmas behind them, and pyc doesn't..

Oh by the way, just got back from the boot sale....Jim and his pyc crew were there...first time they've ever made a profit 😂

[tonytony4] 06/9/2020 09:57

Good posts stig. Will be adding as and when I can... That is if it doesn't take off! Interesting times ahead gla genuine holders.

[the stigologist] 06/9/2020 09:51

Why PYC Physiomics stock could EXPLODE higher in September 2020

Share Price : 8p
Shares in issue : 97m
Market Cap : £8m
Cash : £1m
Revenue : £0.8m p.a.

This comment (see Fig.1) was shared on VAL Valirx BB's this weekend

Clearly knowledgeable VAL investors are very bullish on the upcoming VAL201 Phase I/II Clinical Trial results in Prostate Cancer (due in next few days/weeks)

IF (still a big IF) VAL201 results are good they look like they will be in prime position to licence their VAL201 drug to a Big Pharma

THREE/FOUR MAJOR POTENTIAL POSITIVES FOR PHYSIOMICS from Valirx's VAL201 success

1. IF VAL licence VAL201 Physiomics are entitled to 'Share of ANY licensing income' (licensing income includes i) Upfront fees ii) Development Milestones iii) Royalties when drug goes on Commercial sale. This could be UTTERLY TRANSFORMATIONAL to Physiomics finances and business.
See Fig.5 for examples of Pharma licensing deal values. Any FREE share of those sort of revenues in event of VAL201 showing good results in Phase I/II and then being licensed to a Mid/Big Cap Pharma will be HUGE news for £8m Market Cap ; £0.8m revenue / P&L breakeven Physiomics.

2. IF VAL201 is successful it will have proven that VAL's approach of SRC Inhibition is important and successful this is likely to lead to
i) VAL using Physiomics modelling and simulation knowledge of SRC Inhibition pathways for further work on VAL201 or ii) improved 2nd generation devleopments of VAL201, this may also mean iii) more Modelling and Simulation work from whoever VAL partners VAL201 with

3. Physiomics success in Modelling and Simulation of the SRC Inhibition pathway may also mean other Cancer drug companies working on this pathway also come to Physiomics for help in developing their drugs. It is worth noting
i) The biggest currently selling Prostate Cancer drug is Astellas's Xtandi (about $2bn+ p.a.)
ii) Physiomics recently signed up Astellas (19th Largest Pharma in the World) as a client on a mystery cancer drug project

4. There are suggestions that SRC inhibition is important in other disease pathways. Maybe even Covid19. Could Physiomics knowledge of these pathways and work at the leading edge of Cancer modelling with likes of Merck and Astellas help Companies in their investigation of other SRC Inhibition drugs? Or Combining SRC Inhibition drugs with leading Immuno-Oncology drugs such as Keytruda/Opdivo ?


Fig.1 Grace83 post on VAL LSE BB



Fig.2 Valirx/University College London poster presentation on VAL201





Fig.3 Physiomics tweet in August mentioning VAL201 and their other work with Cancer drugs which are demonstrating potential COVID efficacy



Fig.4 Valirx CEO Suzi Dilly confirming that the Valirx-Physiomics revenue share agreement dating from 2011 remains in place



Fig.5 Potential Upfront Licence Fees Pharma Companies Pay in Phase I,II,III deals (2011-16)

[the stigologist] 06/9/2020 09:49

I do think sometimes there is some psychological equivalence of physical phenomena in Share Prices which may be why for examples Fibonacci series retracements apply to share charts in some cases

I believe there may be an example being demonstrated in the PYC share chart

In November 2017 we had
1. Boom 1p to 32p
2. Smaller Boom 5p to 12.5p
3. Smaller echo Boom 4p to 8p

Now it looks like we may be having a symmetrical opposite Explosive rather than Dampening Boom going on ?

Each Boom seems to be getting bigger. Maybe the 3rd Boom will be the Biggest ? That would tally with the big potential news catalysts we have due ?

[davevt] 06/9/2020 09:26

I love how they try SOO hard 🤣

[hodhasharon] 06/9/2020 07:52

“So excited about this I'm adding next week”

I will add too.

This is going to be a month of huge rises in SP, we’re talking biblical proportions....

[the stigologist] 05/9/2020 22:28

Buckle up folks.

Two very exciting updates to share tomorrow.

September WILL be EXPLOSIVE for Physiomics

So excited about this I'm adding next week

Telegram group is the best forum for 'debate'

>>> You just need Telegram app on your smartphone which you can download from Apple store or Google Playstore

[davevt] 05/9/2020 22:26

No Tony, reduced growth.

Because pyc is the only company that hasn't expanded it's skills. It's still doing what it's only done, where as all it's competitors do what pyc do and 100 times more.

They charge 35 grand per cancer drug. How many cancer drugs are designed a year by big pharma? A handful.

Hence why pyc has never made any decent revenues and never will. It's a niche of a tiny tiny market, and they are outclassed by all their competitors.

Hence why they have hardly any customers, hardly any revenue, and never made a profit.

If they weren't floated and surviving off of placings and grants, they would have closed shop a decade ago. They wouldn't be able to keep the doors open if they relied on revenues.

[tonytony4] 05/9/2020 19:52

Weekend reading plenty of growth for PYC!!

[albert3591] 05/9/2020 07:03

Take more water with your drink sonny.lol